Clinical trial · Observational
Alternative Splicing and Leukemia Initiating Cells
NCT03156933CI-TRIAL-00027623ASLICunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukaemia (AML) are frequent. It have been shown that some splicing variants had a prognostic value in AML. AML are characterized by their propensity to relapse because of the persistence of leukaemia initiating cells (LICs). The aim of this study is to determine the splice variants on AML initiator cells and define a splicing pattern.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Assessment of splicing variants | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Splicing variants
- description
- Sample of acute myeloid leukaemia primary cells
- interventionNames
- Other: Assessment of splicing variants
Primary outcomes (2)
- measure
- Polymerase chain reaction
- timeFrame
- 1 month
- description
- Transcriptome analysis to determine the splicing variants on acute myeloid leukaemia initiator cells. The analysis will focus on the gene encoding ABCA3 transporter and genes known to be mutated in patients with acute myeloid leukemia (FLT3, NPM1, c-Kit, N et K-RAS). The duration of selection of samples is estimated to be one month.
- measure
- Ribonucleic acid sequencing
- timeFrame
- 1 month
- description
- Transcriptome analysis to determine the splicing variants on acute myeloid leukaemia initiator cells. The analysis will focus on the gene encoding ABCA3 transporter and genes known to be mutated in patients with acute myeloid leukemia (FLT3, NPM1, c-Kit, N et K-RAS). The duration of selection of samples is estimated to be one month.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years-old * Patients treated at the south lyon hospital center * Patients with a diagnosis of acute myeloid leukemia confirmed in cytology and whose involvement of the 11q23 locus was confirmed by in situ hybridization * Patients for whom a sample is available in the cytogenetic laboratory of the south lyon hospital center Exclusion Criteria: None
References
Publications (0)
Data not yet available
No reference posted for this study.